You are here: Industry Insights > Lilly

News List

Lilly signs licensing agreements with Dr Reddy’s, MSN Labs and Torrent Pharma for Baricitinib expresspharma
May 14, 2021
On May 10, Lilly had also announced the signing of three Voluntary License Agreements with Cipla, Lupin and Sun Pharma Industries.
Lilly and MiNA Therapeutics enter deal to develop saRNA-based drugs pharmaceutical-technology
May 13, 2021
Eli Lilly and MiNA Therapeutics have entered a global research partnership to develop new drug candidates using the latter’s small activating RNA (saRNA) technology platform.
Lilly plans donation of COVID-19 therapies to Direct Relief for use in low- and lower-middle-income countries worldpharmanews
May 11, 2021
Eli Lilly and Company is donating COVID-19 therapies to Direct Relief, enabling the humanitarian organization to provide COVID-19 therapies at no cost to low- and lower-middle-income countries most heavily impacted by the pandemic.
Lilly signs licensing agreements with Cipla, Lupin and Sun Pharma for Baricitinib in India expresspharma
May 11, 2021
Eli Lilly and Company announced that it has issued royalty-free, non-exclusive voluntary licenses to established Indian pharmaceutical manufacturers of generic medicines, Cipla, Lupin and Sun Pharmaceutical Industries, who are collaborating with Lilly ...
Cipla signs licensing deal with Lilly to manufacture and commercialise baricitinib in India expresspharma
May 10, 2021
Baricitinib was issued a restricted emergency use approval by CDSCO to treat COVID-19.
Baricitinib enhances hair regrowth for alopecia areata patients europeanpharmaceuticalreview
April 22, 2021
New Phase III data shows once daily treatment with baricitinib significantly increases hair regrowth in adult patients with severe alopecia areata.
Innovent and Lilly Release Phase 3 Results of TYVYT® (Sintilimab Injection) as a Second-Line Treatment for Squamous Non-Small Cell Lung Cancer at AACR Annual Meeting 2021 prnasia
April 13, 2021
Innovent Biologics, Inc. announced with Eli Lilly and Company that the results of the Phase 3 ORIENT-3 study were released in an oral presentation at the American Association for Cancer Research (AACR) Annual Meeting 2021.
Lilly, Incyte's Olumiant fails in COVID-19 trial pharmatimes
April 13, 2021
A Phase III trial of Eli Lilly and Incyte's baricitinib has failed to meet its primary endpoint in patients hospitalised with COVID-19.
Lilly Modifies Purchase Agreement with U.S. for COVID Therapies contractpharma
April 13, 2021
Bamlanivimab and etesevimab agreement modified to enable the supply of etesevimab to complement doses of bamlanivimab the U.S. government already purchased.
Lilly, Incyte report trial results of baricitinib in Covid-19 patients pharmaceutical-technology
April 09, 2021
Eli Lilly and Incyte have reported that the Phase III COV-BARRIER study of baricitinib failed to meet statistical significance on the primary endpoint of progression to non-invasive ventilation or invasive mechanical ventilation or death in ...

Previous page 1 2 3 4 5 6 7 8 9 10 ... 25 26 Next page